AURLUMYN

Growth

iloprost

Johnson & Johnson

NDAINTRAVENOUSSOLUTIONPriority Review

Approved

Feb 2024

Lifecycle

Growth

Competitive Pressure

0/100

Clinical Trials

Data completeness

6/8 — Strong

Priority Review

AURLUMYN (iloprost) by Johnson & Johnson is 2 . Approved for pulmonary hypertension, pulmonary arterial hypertension. First approved in 2024.

Drug data last refreshed 20h ago

Mechanism of Action

2 . Iloprost is a vasodilator and inhibits platelet aggregation.

Pharmacologic Class:

Prostacycline

Indications (2)

Pulmonary Hypertension(14)Pulmonary Arterial Hypertension

Worked on AURLUMYN at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (17)

NCT04123444Phase 2/3Completed

Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in Patients With Septic Shock Suffering From Organ Failure

Started Oct 2019

279 enrolled

Septic Shock

NCT04040322Phase 3Completed

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)

Started Oct 2019

198 enrolled

Raynaud's Phenomenon Secondary to Systemic Sclerosis

NCT03867097Phase 2Completed

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)

Started Mar 2019

34 enrolled

Raynaud Phenomenon Secondary to Systemic Sclerosis

NCT03293407N/ACompleted

Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension

Started Feb 2018

31 enrolled

Hypertension, Pulmonary

NCT02826252N/ACompleted

Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)

Started Sep 2016

64 enrolled

Hypertension, Pulmonary